The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Clinical and correlative science results in a phase II study of UCN-01 in combination with irinotecan in recurrent triple-negative breast cancer (TNBC).
Cynthia X. Ma
No relevant relationships to disclose
Matthew J. Ellis
Other Remuneration - PAM 50, Bioclassifier LLC, patent and Licensing
Gina R. Petroni
No relevant relationships to disclose
A. Craig Lockhart
No relevant relationships to disclose
Michael Naughton
No relevant relationships to disclose
Timothy J. Pluard
No relevant relationships to disclose
Christiana Brenin
No relevant relationships to disclose
Joel Picus
No relevant relationships to disclose
Allison N Creekmore
No relevant relationships to disclose
Tibu N. Mwandoro
No relevant relationships to disclose
Zhanfang Guo
No relevant relationships to disclose
Shirong Cai
No relevant relationships to disclose
Christine Ryan
No relevant relationships to disclose
Erin Yarde
No relevant relationships to disclose
Jeremy Hoog
No relevant relationships to disclose
Janet Dancey
No relevant relationships to disclose
Mark Watson
No relevant relationships to disclose
Helen Piwnica-Worms
No relevant relationships to disclose
Paula M. Fracasso
No relevant relationships to disclose